MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,282K
Free Cash flow
-$7,284K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Prepaid clinical trial costs (cu...
Stock-based compensation
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Gain on settlement of accounts p...
Consolidated net loss
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Depreciation and amortization
48
55
50
288
(gain) loss on sale of property and equipment
0
0
54
-81
Change in deferred income taxes
-
-
-
-165
Gain on settlement of accounts payable and convertible notes payable
3,723
201
34
-
Stock-based compensation
172
387
598
2,123
Gain on dtlm sale transactions
-
-
-
30
Trade accounts receivable
-1
-118
-214
151
Inventory
5
-1
-9
11
Prepaid expenses and other current assets
-1
360
-273
-818
Prepaid clinical trial costs (current and non-current)
-310
1,260
-231
-112
Other receivables
0
0
-1,206
273
Other assets
52
-1
-5
-28
Accounts payable and accrued expenses
-1,138
505
457
-922
Other current liabilities
4
3
-3
-67
Due to related parties
-18
-18
28
-10
Accrued expenses, noncurrent
0
-415
3
913
Convertible notes payable
14
-12
8
5
Consolidated net loss
-2,898
-6,327
-9,797
-30,643
Amortization of discount on available-for-sale securities
0
0
0
-285
Loss on impairment of goodwill
0
0
-
3,050
Unrealized loss on equity investments - cyclo
0
0
0
-5,144
Gain on dtlm sale transactions
0
-
-
-
Interest receivable
0
0
0
-515
Other liabilities
0
0
0
15
Realized gain on available-for-sale securities
0
0
0
178
Unrealized loss on convertible notes, due from cyclo
0
0
0
-719
Net unrealized gain on investments - hedge funds
-
-
-
0
Realized loss on investment in equity securities
-
-
-
0
Loss on initial investment in day three upon acquisition
-
-
-
0
Realized gain on equity investments - cyclo
-
-
-
0
Recovery of receivables from cornerstone
-
-
-
0
In-process research and development expense
-
-
-
0
Gain on dissolution of a business
-
-
-
0
Equity in loss of day three
-
-
-
0
Credit loss expense
-
-
-
0
Net cash used in operating activities
-7,284
-7,523
-6,806
-18,924
Purchase of property and equipment
0
5
0
4
Proceeds from sale of property and equipment
6
0
70
13
Purchase of preferred shares and warrants from nina medical
0
250
500
-
Purchases of available-for-sale securities
0
0
0
16,988
Proceeds from the sale and maturities of available-for-sale securities
0
0
0
80,694
Purchase of intangible assets
0
0
0
17
Payments for convertible notes receivable, due from cyclo
-
-
-
19,500
Issuance of convertible notes, due from cyclo
0
0
0
-
Cash paid in cyclo merger, net of cash acquired
0
-
-
2,709
Proceeds from hedge funds
0
0
-
2,547
Proceeds from day three patent sale
-
-
-
0
Proceeds from sales of equity securities
-
-
-
0
Issuance of convertible notes receivable, due from cyclo
-
-
-
0
Purchase of investments in cyclo
-
-
-
0
Issuance of convertible note receivable
-
-
-
0
Issuance of day three promissory notes
-
-
-
0
Proceeds from investments - other pharmaceuticals
-
-
-
0
Cash acquired in acquisition of day three, net of cash payments
-
-
-
0
Cash acquired in the cornerstone acquisition, net of cash payments
-
-
-
0
Net cash (used in) provided by investing activities
6
-255
-430
44,035
Payments for taxes related to shares withheld for employee taxes
19
32
28
215
Proceeds from issuance of common stock in rights offering, net of transaction costs
-
-
-
25,001
Proceeds from sale of rafael medical devices membership units
-
-
-
44
Principal payments on installment note payable
-
-
-
0
Cash paid to settle convertible notes payable
9
0
2
-
Purchases of treasury stock
-
-
-
0
Proceeds from sale of rafael medical devices membership units
0
-
-
-
Net cash used in financing activities
-28
-32
-30
24,830
Effect of exchange rate changes on cash and cash equivalents
24
50
36
153
Net (decrease) increase in cash and cash equivalents
-7,282
-7,760
-7,230
50,094
Cash and cash equivalents, beginning of period
45,539
45,539
52,769
2,675
Cash and cash equivalents, end of period
30,497
37,779
45,539
52,769
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
property and equipment
$6K
Effect of exchange rate
changes on cash and cash...
$24K
Net cash (used in)
provided by investing...
$6K
Net (decrease)
increase in cash and cash...
-$7,282K
Canceled cashflow
$30K
Prepaid clinical trial
costs (current and...
-$310K
Stock-based compensation
$172K
Depreciation and
amortization
$48K
Convertible notes payable
$14K
Other current
liabilities
$4K
Prepaid expenses and
other current assets
-$1K
Trade accounts
receivable
-$1K
Net cash used in
operating activities
-$7,284K
Canceled cashflow
$550K
Net cash used in
financing activities
-$28K
Gain on settlement of
accounts payable and...
$3,723K
Consolidated net loss
-$2,898K
Accounts payable and
accrued expenses
-$1,138K
Other assets
$52K
Due to related
parties
-$18K
Inventory
$5K
Payments for taxes
related to shares...
$19K
Cash paid to settle
convertible notes payable
$9K
Buy us a coffee
Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. (RFL)